| Assay ID | Title | Year | Journal | Article |
|---|
| AID1347119 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347127 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347124 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347116 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347115 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347118 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347129 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347113 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347110 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347128 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347109 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347122 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347117 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347112 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347125 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347126 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347123 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347114 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347111 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347121 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347412 | qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347414 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347415 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: tertiary screen by RT-qPCR | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID421316 | Inhibition of Hsp90 in human AU565 cells assessed as pERK degradation after 24 hrs by high content screening | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
| Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. |
| AID697737 | Cytotoxicity against african green monkey Vero cells assessed as inhibition of cell viability after 48 hrs by MTT assay | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
| Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors. |
| AID716064 | Intrinsic clearance in human liver microsomes | 2012 | Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
| EC144 is a potent inhibitor of the heat shock protein 90. |
| AID1363694 | Inhibition of FITC-geldanamycin binding to dog GST-tagged GRP94 N41 deletion mutant (69 to 337 residues) expressed in Escherichia coli BL21star (DE3) after 4 hrs by GM-FITC-based FP assay | 2018 | Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21
| Discovery of a Potent Grp94 Selective Inhibitor with Anti-Inflammatory Efficacy in a Mouse Model of Ulcerative Colitis. |
| AID421319 | Solubility of the compound | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
| Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. |
| AID697736 | Antiviral activity against HSV1 strain F ATCC VR733 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect after 48 hrs by plaque reduction assay | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
| Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors. |
| AID697722 | Antiviral activity against HSV1 infected herpes simplex keratitis New zealand rabbit model assessed as reduction in viral DNA level in corneal sample compound administered twice daily as gel 24 hrs post inoculation measured on day 9 post infection by RT-P | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
| Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors. |
| AID1491574 | Antileishmanial activity against Leishmania donovani axenic amastigotes infected in mouse J774 cells after 72 hrs by Draq5 staining based assay | 2017 | ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8
| Synthesis and Activity of a New Series of Antileishmanial Agents. |
| AID421306 | Antiproliferative activity against human HT-29 cells after 72 to 144 hrs by cyquant DNA dye method | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
| Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. |
| AID465293 | Binding affinity to HSP90 under non-reducing conditions in absence of TECP | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
| Heat shock protein 90: inhibitors in clinical trials. |
| AID697732 | Antiviral activity against HSV2 strain 333 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect at 4 uM after 48 hrs by plaque reduction assay | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
| Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors. |
| AID1708084 | Inhibition of FITC-GDA binding to dog GRP94 incubated for 2 hrs by fluorescence polarization assay | 2021 | Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
| The Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with |
| AID716069 | Fraction unbound at mouse plasma | 2012 | Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
| EC144 is a potent inhibitor of the heat shock protein 90. |
| AID716066 | Intrinsic clearance in mouse liver microsomes | 2012 | Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
| EC144 is a potent inhibitor of the heat shock protein 90. |
| AID421309 | Antiproliferative activity against human PC3 cells after 72 to 144 hrs by cyquant DNA dye method | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
| Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. |
| AID716065 | Intrinsic clearance in rat liver microsomes | 2012 | Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
| EC144 is a potent inhibitor of the heat shock protein 90. |
| AID1708085 | Inhibition of FITC-GDA binding to human TRAP1 incubated for 2 hrs by fluorescence polarization assay | 2021 | Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
| The Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with |
| AID421312 | Antiproliferative activity against human HCT15 cells after 72 to 144 hrs by cyquant DNA dye method | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
| Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. |
| AID421300 | Inhibition of Hsp90 in human AU565 cells assessed as Her2 degradation after 24 hrs by high content screening | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
| Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. |
| AID716068 | Fraction unbound at rat plasma | 2012 | Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
| EC144 is a potent inhibitor of the heat shock protein 90. |
| AID465289 | Binding affinity to HSP90 under reducing conditions in presence of TECP | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
| Heat shock protein 90: inhibitors in clinical trials. |
| AID780857 | Displacement of FITC-Geldanamycin from Hsp90 (unknown origin) after 18 hrs by fluorescence polarization assay | 2013 | Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
| Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90). |
| AID1708083 | Inhibition of FITC-GDA binding to human HSP90-alpha incubated for 2 hrs by fluorescence polarization assay | 2021 | Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
| The Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with |
| AID421308 | Antiproliferative activity against human SK-MEL-5 cells after 72 to 144 hrs by cyquant DNA dye method | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
| Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. |
| AID465362 | Half life in plasma of mouse bearing human MM1S cells at 50 mg/kg | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
| Heat shock protein 90: inhibitors in clinical trials. |
| AID421299 | Oral bioavailability in mouse | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
| Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. |
| AID1491576 | Inhibition of human Hsp90 by fluorescence polarization analysis | 2017 | ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8
| Synthesis and Activity of a New Series of Antileishmanial Agents. |
| AID697735 | Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
| Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors. |
| AID697727 | Antiviral activity against HSV1 infected herpes simplex keratitis New zealand rabbit model at 0.025% to 0.1% administered twice daily as gel 24 hrs post inoculation measured on day 9 post infection | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
| Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors. |
| AID1063122 | Binding affinity to human recombinant TRAP1 after 3 hrs by fluorescence polarization assay | 2014 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
| Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases. |
| AID697733 | Antiviral activity against HSV1 strain F ATCC VR733 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect at 4 uM after 48 hrs by plaque reduction assay | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
| Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors. |
| AID421314 | Inhibition of Hsp90 in human A375 cells assessed as Hsp70 induction after 24 hrs by high content screening | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
| Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. |
| AID697723 | Antiviral activity against HSV1 infected herpes simplex keratitis New zealand rabbit model assessed as reduction in viral DNA level in corneal sample at 0.025% to 0.1% administered twice daily as gel 24 hrs post inoculation measured on day 9 post infectio | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
| Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors. |
| AID421315 | Inhibition of Hsp90 in human A375 cells assessed as pS6 degradation after 24 hrs by high content screening | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
| Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. |
| AID421318 | Metabolic stability in human liver S9 fraction assessed as drug remaining at 1 uM after 1 hr | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
| Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. |
| AID1491573 | Antileishmanial activity against Leishmania donovani axenic amastigotes after 72 hrs by CellTiter reagent based assay | 2017 | ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8
| Synthesis and Activity of a New Series of Antileishmanial Agents. |
| AID1604479 | Displacement of FITC-geldanamycin from HSP90alpha (unknown origin) after 5 hrs by fluorescence polarization assay | 2020 | Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
| Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions. |
| AID421304 | Antiproliferative activity against human LNCAP cells after 72 to 144 hrs by cyquant DNA dye method | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
| Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. |
| AID421303 | Antiproliferative activity against human A375 cells after 72 to 144 hrs by cyquant DNA dye method | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
| Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. |
| AID716071 | Inhibition of Hsp90alpha | 2012 | Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
| EC144 is a potent inhibitor of the heat shock protein 90. |
| AID697728 | Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for HSV2 strain 333 infected in african green monkey Vero cells | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
| Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors. |
| AID767754 | Displacement of 5-(3-(3-(6-amino-8-(6-iodobenzo[d][1,3]dioxol-5-ylthio)-9H-purin-9-yl)propyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid from HSP90alpha (unknown origin) after 24 hrs by fluorescence polarization assay | 2013 | Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
| Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series. |
| AID767751 | Displacement of 5-(3-(3-(6-amino-8-(6-iodobenzo[d][1,3]dioxol-5-ylthio)-9H-purin-9-yl)propyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid from recombinant human Trap-1 after 24 hrs by fluorescence polarization assay | 2013 | Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
| Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series. |
| AID716070 | Efflux ratio of apparent permeability from basolateral to apical side to apical to basolateral side of human Caco2 cells | 2012 | Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
| EC144 is a potent inhibitor of the heat shock protein 90. |
| AID716052 | Half life in CD-1 mouse at 25 mg/kg, po | 2012 | Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
| EC144 is a potent inhibitor of the heat shock protein 90. |
| AID421302 | Binding affinity to pig spleen Hsp90 ATPase pocket by Bradford assay | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
| Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. |
| AID421307 | Antiproliferative activity against human SW620 cells after 72 to 144 hrs by cyquant DNA dye method | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
| Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. |
| AID697729 | Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for HSV1 strain F ATCC VR733 infected in african green monkey Vero cells | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
| Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors. |
| AID1063124 | Binding affinity to human N-terminal polyHis-tagged HSP90beta (D9 to E236) expressed in insect sf9 cells after 3 hrs by fluorescence polarization assay | 2014 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
| Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases. |
| AID697734 | Antiviral activity against HSV2 strain 333 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect after 48 hrs by plaque reduction assay | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
| Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors. |
| AID716061 | Tmax in CD-1 mouse at 25 mg/kg, po | 2012 | Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
| EC144 is a potent inhibitor of the heat shock protein 90. |
| AID421317 | Metabolic stability in human liver microsomes at 1 uM after 1 hr | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
| Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. |
| AID1363696 | Inhibition of FITC-geldanamycin binding to human His-tagged HSP90alpha N-terminal domain (1 to 236 residues) expressed in Escherichia coli BL21star (DE3) after 4 hrs by FP assay relative to control | 2018 | Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21
| Discovery of a Potent Grp94 Selective Inhibitor with Anti-Inflammatory Efficacy in a Mouse Model of Ulcerative Colitis. |
| AID465281 | Inhibition of HSP90-mediated client protein HER2 degradation in human MCF7 cells | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
| Heat shock protein 90: inhibitors in clinical trials. |
| AID1708082 | Inhibition of FITC-GDA binding to human HSP90-beta incubated for 2 hrs by fluorescence polarization assay | 2021 | Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
| The Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with |
| AID716077 | Apparent permeability from apical to basolateral side of human Caco2 cells | 2012 | Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
| EC144 is a potent inhibitor of the heat shock protein 90. |
| AID1604480 | Displacement of FITC-geldanamycin from GRP94 (unknown origin) after 5 hrs by fluorescence polarization assay | 2020 | Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
| Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions. |
| AID1491575 | Cytotoxicity against mouse J774.A1 cells after 72 hrs by MTS assay | 2017 | ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8
| Synthesis and Activity of a New Series of Antileishmanial Agents. |
| AID767752 | Displacement of 5-(3-(3-(6-amino-8-(6-iodobenzo[d][1,3]dioxol-5-ylthio)-9H-purin-9-yl)propyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid from dog Grp94 after 24 hrs by fluorescence polarization assay | 2013 | Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
| Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series. |
| AID716076 | Inhibition of HSP90alpha in human MCF7 cells assessed as degradation of Her-2 | 2012 | Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
| EC144 is a potent inhibitor of the heat shock protein 90. |
| AID716078 | Initial Cmax in CD-1 mouse at 25 mg/kg, po | 2012 | Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
| EC144 is a potent inhibitor of the heat shock protein 90. |
| AID1063123 | Binding affinity to human N-terminal polyHis-tagged GRP94 (L69 to N337) expressed in Escherichia coli BL21(DE3) after 3 hrs by fluorescence polarization assay | 2014 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
| Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases. |
| AID465363 | Half life in tumor of mouse bearing human MM1S cells at 50 mg/kg | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
| Heat shock protein 90: inhibitors in clinical trials. |
| AID1063127 | Binding affinity to human N-terminal polyHis-tagged HSP90alpha (D9 to E236) alpha-helix conformation expressed in insect sf9 cells after 3 hrs by fluorescence polarization assay | 2014 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
| Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases. |
| AID421313 | Antiproliferative activity against human K562 cells after 72 to 144 hrs by cyquant DNA dye method | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
| Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. |
| AID767753 | Displacement of 5-(3-(3-(6-amino-8-(6-iodobenzo[d][1,3]dioxol-5-ylthio)-9H-purin-9-yl)propyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid from recombinant HSP90beta (unknown origin) after 24 hrs by fluorescence polarization assay | 2013 | Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
| Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series. |
| AID1363693 | Inhibition of FITC-geldanamycin binding to dog GST-tagged GRP94 N41 deletion mutant (69 to 337 residues) expressed in Escherichia coli BL21star (DE3) at 100 uM after 4 hrs by FP assay relative to control | 2018 | Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21
| Discovery of a Potent Grp94 Selective Inhibitor with Anti-Inflammatory Efficacy in a Mouse Model of Ulcerative Colitis. |
| AID421311 | Antiproliferative activity against human NCI-H460 cells after 72 to 144 hrs by cyquant DNA dye method | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
| Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. |
| AID716067 | Fraction unbound at human plasma | 2012 | Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
| EC144 is a potent inhibitor of the heat shock protein 90. |
| AID421310 | Antiproliferative activity against human MDA-MB-231 cells after 72 to 144 hrs by cyquant DNA dye method | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
| Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. |
| AID716058 | AUC in CD-1 mouse at 25 mg/kg, po | 2012 | Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
| EC144 is a potent inhibitor of the heat shock protein 90. |
| AID421320 | Aqueous solubility in phosphate-buffered saline at pH 7.4 | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
| Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. |
| AID465283 | Inhibition of HSP90-mediated client protein HER2 degradation | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
| Heat shock protein 90: inhibitors in clinical trials. |
| AID1170902 | Increase in oxygen consumption rate/extracellular acidification rate ratio in human NCI-H1299 cells at incubated for 12 hrs | 2014 | Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
| Discovery and optimization of 4,5-diarylisoxazoles as potent dual inhibitors of pyruvate dehydrogenase kinase and heat shock protein 90. |
| AID697724 | Antiviral activity against HSV1 infected herpes simplex keratitis New zealand rabbit model assessed as reduction in corneal epithelia involvement score at 0.025% to 0.1% administered twice daily as gel 24 hrs post inoculation measured on day 9 post infect | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
| Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors. |
| AID716055 | Dose normalized AUC in CD-1 mouse at 25 mg/kg, po | 2012 | Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
| EC144 is a potent inhibitor of the heat shock protein 90. |
| AID421305 | Antiproliferative activity against human MCF7 cells after 72 to 144 hrs by cyquant DNA dye method | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
| Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. |
| AID977610 | Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB | 2014 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
| Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |